BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 16358941)

  • 21. [Neuroendocrine tumours of the gastrointestinal tract].
    Plöckinger U; Wiedenmann B
    Z Gastroenterol; 2004 Jun; 42(6):517-27. PubMed ID: 15190448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin, cortistatin and their receptors in tumours.
    Volante M; Rosas R; Allìa E; Granata R; Baragli A; Muccioli G; Papotti M
    Mol Cell Endocrinol; 2008 May; 286(1-2):219-29. PubMed ID: 18248880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.
    Appetecchia M; Baldelli R
    J Exp Clin Cancer Res; 2010 Mar; 29(1):19. PubMed ID: 20196864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
    Giustina A; Mazziotti G; Maffezzoni F; Amoroso V; Berruti A
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1619-35. PubMed ID: 25060168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
    Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
    Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy.
    Oberg K; Ferone D; Kaltsas G; Knigge UP; Taal B; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):209-13. PubMed ID: 19077379
    [No Abstract]   [Full Text] [Related]  

  • 27. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
    Toumpanakis C; Caplin ME
    Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
    Grozinsky-Glasberg S; Grossman AB; Korbonits M
    Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Somatostatin, somatostatin analogs and their clinical use].
    Krsek M
    Cas Lek Cesk; 2003 Mar; 142(3):134-8; discussion 139. PubMed ID: 12756839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment.
    Reubi JC
    Neuroendocrinology; 2004; 80 Suppl 1():51-6. PubMed ID: 15477718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
    Narayanan S; Kunz PL
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
    Oberg K; Kvols L; Caplin M; Delle Fave G; de Herder W; Rindi G; Ruszniewski P; Woltering EA; Wiedenmann B
    Ann Oncol; 2004 Jun; 15(6):966-73. PubMed ID: 15151956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The somatostatin receptor subtype 5 in neuroendocrine tumours.
    van der Hoek J; Lamberts SW; Hofland LJ
    Expert Opin Investig Drugs; 2010 Mar; 19(3):385-99. PubMed ID: 20151855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Polish diagnostic and therapeutic guidelines in gastroenteropancreatic neuroendocrine tumors (GEP NET)].
    Kos-Kudła B;
    Endokrynol Pol; 2006; 57(3):267-72. PubMed ID: 17111342
    [No Abstract]   [Full Text] [Related]  

  • 36. [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
    Bodelier AG; Haak HR
    Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1868-72. PubMed ID: 16970007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastroenteropancreatic neuroendocrine tumours: an overview.
    Davies L; Weickert MO
    Br J Nurs; 2016 Feb 25-Mar 9; 25(4):S12-5. PubMed ID: 26911175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnosis of neuroendocrine tumours in the gastrointestinal tract].
    Rehfeld JF; Friis-Hansen L; Gøtze JP; Hilsted L; Nielsen FC
    Ugeskr Laeger; 2010 Oct; 172(43):2957-60. PubMed ID: 21040675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view.
    Prasad V; Fetscher S; Baum RP
    J Pharm Pharm Sci; 2007; 10(2):321s-337s. PubMed ID: 17718935
    [No Abstract]   [Full Text] [Related]  

  • 40. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
    Janson ET
    J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.